AB Corporate Bond ETF (NASDAQ:EYEG) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

AB Corporate Bond ETF (NASDAQ:EYEG)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.78 and traded as low as $35.37. AB Corporate Bond ETF shares last traded at $35.37, with a volume of 15 shares traded.

AB Corporate Bond ETF Price Performance

The business has a fifty day moving average of $35.42 and a 200 day moving average of $35.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. The stock has a market cap of $28.30 million, a PE ratio of -21.05 and a beta of 0.18.

AB Corporate Bond ETF Dividend Announcement

The firm also recently announced a monthly dividend, which was paid on Wednesday, May 6th. Stockholders of record on Friday, May 1st were paid a dividend of $0.1404 per share. This represents a c) annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Friday, May 1st. AB Corporate Bond ETF’s dividend payout ratio is -103.57%.

Institutional Trading of AB Corporate Bond ETF

A number of hedge funds and other institutional investors have recently made changes to their positions in EYEG. Jane Street Group LLC bought a new position in AB Corporate Bond ETF during the 2nd quarter valued at $232,000. Wealth Enhancement Advisory Services LLC increased its position in shares of AB Corporate Bond ETF by 6.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 119,017 shares of the specialty pharmaceutical company’s stock worth $4,301,000 after purchasing an additional 6,988 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of AB Corporate Bond ETF in the 4th quarter worth about $34,000. Institutional investors own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.